SARS-CoV-2 vaccination and phase 1 cancer clinical trials

Affiliations

¹ Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: tyap@mdanderson.org.
² Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
³ Early Phase Clinical Drug Development in Oncology, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
⁴ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
⁵ Early Phase Clinical Trials Program, Yale University Medical Center, New Haven, CT, USA.
⁶ Department of Drug Development, Gustave Roussy Cancer Institute, University Paris Saclay, Villejuif, France.
⁷ Northern Institute for Cancer Care, Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK.
⁸ The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.
⁹ Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.

Timothy A Yap et al. Lancet Oncol. 2021 Mar.

. 2021 Mar;22(3):298-301.

doi: 10.1016/S1470-2045(21)00017-6. Epub 2021 Feb 8.

¹ Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: tyap@mdanderson.org.
² Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
³ Early Phase Clinical Drug Development in Oncology, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
⁴ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
⁵ Early Phase Clinical Trials Program, Yale University Medical Center, New Haven, CT, USA.
⁶ Department of Drug Development, Gustave Roussy Cancer Institute, University Paris Saclay, Villejuif, France.
⁷ Northern Institute for Cancer Care, Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK.
⁸ The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.
⁹ Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.

No abstract available

Figures

1. European Society for Medical Oncology ESMO statements for vaccination against COVID-19 in patients with cancer. https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383:1920–1931. - PMC - PubMed
1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397:99–111. - PMC - PubMed
1. Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31:1320–1335. - PMC - PubMed